Contact Dermatitis – Drugs In Development, 2024
Powered by ![]()
Unlock hidden opportunities in the Pharmaceuticals industry
Empower your strategies with our Contact Dermatitis – Drugs In Development, 2024 report and make more profitable business decisions.
Contact dermatitis is a type of skin inflammation that occurs when substances touching the skin cause irritation or an allergic reaction. Signs and symptoms of contact dermatitis include red rash or bumps and dry, cracked, red patches, which may resemble a burn, and pain or tenderness. There are two types of contact dermatitis: irritant and allergic. Irritant dermatitis, the most common type, is caused by contact with acids, alkaline materials such as soaps and detergents, fabric softeners, solvents, or other chemicals. The reaction usually looks like a burn. Allergic contact dermatitis is an itchy skin condition caused by an allergic reaction to an allergen. Treatment includes oral corticosteroids and antihistamines to relieve intense itching.
The Contact Dermatitis drugs in development market research report provide comprehensive information on the therapeutics under development for Contact Dermatitis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action and product description of the therapeutics, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Contact Dermatitis and features dormant and discontinued products.
Note:
* This is an “on-demand” report and will be delivered within 2 business days (excluding weekends and holidays) of the purchase.
* Certain sections in the report may be removed or altered based on the availability and relevance of data.
| Quick View – Contact Dermatitis | Key Targets |
|
|
| Key Mechanisms of Action |
|
||
| Key Routes of Administration |
|
||
| Key Molecule Types |
|
||
| Major Companies |
|
||
Scope
- Therapeutics in Development: Covering 11 molecules, with 10 developed by companies and the rest by universities/institutes.
- Analysis Parameters: Offering insights by stage of development, drug target, MoA, RoA, and molecule type for a comprehensive overview.
- Pharmacological Insights: Understand the descriptive pharmacological action of therapeutics.
- Development History: Access the complete research and development history.
- Latest News and Press Releases: Stay updated with the latest developments through comprehensive news coverage.
Reasons to Buy
- Holistic insights: Understand the broad spectrum of Contact Dermatitis therapeutics, aiding strategic decision-making with insights into stages, targets, MoA, RoA and molecule types.
- Pipeline Exploration: Explore the detailed Contact Dermatitis pipeline, offering nuanced analysis of drug targets, mechanisms of action and routes of administration for varied decision-making.
- Comprehensive R&D: Access thorough R&D histories, providing a comprehensive understanding of Contact Dermatitis treatments for adaptable decision-making.
- Save valuable hours: Identify key players steering innovation in therapeutics, enabling strategic partnerships.
Key Players
Allakos IncAposcience AG
Edesa Biotech Inc
ExpreS2ion Biotech Holding AB
Hapten Sciences Inc
ILiAD Biotechnologies LLC
KARE Biosciences Inc
NextPhase Therapeutics
Signum Dermalogix Inc
Tianjin Institute of Pharmaceutical Research
Table of Contents
Table
Figures
Frequently asked questions
Related reports
View more Contact Dermatitis reports